Thrombolytics in target lesion were not used for 19 of 20 patients treated with next-generation mechanical arterial thrombectomy device EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ : SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that its Pounce™ Thrombectomy System […]
Tag: Surmodics
Surmodics Reports Second Quarter Fiscal 2022 Results
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022. Summary of Second Quarter and Recent […]
Surmodics Reports First Quarter Fiscal 2022 Results
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 first quarter ended December 31, 2021. Summary of First Quarter and Recent Highlights Revenue of $23.0 million, an increase of 3% […]
Surmodics Reports Fourth Quarter Fiscal 2021 Results and Issues Fiscal 2022 Revenue and EPS Guidance
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 fourth quarter ended September 30, 2021 and provided its financial outlook for its fiscal 2022. Summary of Fourth Quarter and Recent […]
Surmodics Announces Successful First Patient Uses of Sublime™ Radial Access .018 RX PTA Dilatation Catheter
Latest addition to the Sublime™ Radial Access Platform expands market opportunity by increasing size offering to treat larger vessels and providing the shaft length needed to treat more distal lesions using a radial approach EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic […]
Surmodics Announces Successful First Patient Use of Pounce™ Thrombectomy System
Standalone arterial mechanical thrombectomy device removes 30 cm of subacute thrombus in first clinical case EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that J. Michael Bacharach, MD, vascular interventionalist/cardiologist at North Central […]
Surmodics Builds Thrombectomy Portfolio with Acquisition of Vetex Medical Limited
Deal adds second FDA 510(k) cleared device to thrombectomy platform Easy-to-use, stand-alone, single session mechanical thrombectomy for removal of venous clot in highly attractive, rapidly growing and significantly under-penetrated market FDA 510(k) cleared (Dec. 2020) and CE Mark Certification (May 2021) 12-month follow-up data of 19-patient feasibility trial presented at […]
Surmodics Announces Successful First Patient Uses of Two Sublime™ Radial Access Platform Devices
Sublime™ Radial Access .014 RX PTA Dilatation Catheter, Sublime Radial Access Guide Sheath Deliver Outstanding Performance in Initial Physician Evaluations EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the successful first uses with patients […]
Surmodics Reports First Quarter Fiscal 2021 Results
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2021 first quarter ended December 31, 2020. Summary of First Quarter and Recent Highlights Revenue of $22.3 million, a decrease of 1% […]
12-Month Data from Surmodics’ TRANSCEND Trial Presented at LINC 2021 Event
SurVeil™ Drug Coated Balloon (DCB) demonstrates non-inferior safety and efficacy, while using a substantially lower drug dose, vs. the IN.PACT® Admiral® DCB for treatment of femoropopliteal lesions. EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that […]